









Markets
/
Stocks
/
nasdaq-crl
/

Charles River Laboratories International Inc

CRL

150.595USD

-1.645-1.08%

Market hours （ET）Quotes delayed by 15 min

7.41BMarket Cap

LossP/E TTM



Charles River Laboratories International Inc

150.595

-1.645-1.08%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-15

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

63 / 507

Overall Ranking

192 / 4724

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 19 analysts

Hold

Current Rating

179.244

Target Price

+17.24%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Charles River Laboratories International, Inc. provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. The Company's Research Models and Services segment is comprised of three businesses that provide foundational tools that enables its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.

Industry Leader

The company's revenue leads the industry, with the latest annual revenue totaling USD 4.05B.

Undervalued

The company’s latest PE is -117.47, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 56.14M shares, decreasing 7.23% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 5.80M shares of this stock.

Financial Health

Currency: USD Updated：2025-09-15

The company's current financial score is 7.75, which is higher than the Biotechnology & Medical Research industry's average of 6.80. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 984.17M, representing a year-over-year decrease of 2.71%, while its net profit experienced a year-over-year decrease of 62.17%.

Score

Industry at a Glance

Previous score

7.75

Change

0.62



Financials

8.30

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.84

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

8.74

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

6.99

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-15

The company’s current valuation score is 1.20, which is lower than the Biotechnology & Medical Research industry's average of 1.64. Its current P/E ratio is -125.61, which is -119.98% below the recent high of 25.10 and 116.79% above the recent low of 21.09.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 63/507

No Data

Earnings Forecast

Currency: USD Updated：2025-09-15

The company’s current earnings forecast score is 6.42, which is lower than the Biotechnology & Medical Research industry's average of 7.96. The average price target for Charles River Laboratories International Inc is 172.50, with a high of 200.00 and a low of 142.00.

Score

Industry at a Glance

Previous score

6.95

Change

Support & Resistance

No Data

Analyst Rating

Based on 19 analysts

Hold

Current Rating

179.244

Target Price

+17.24%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Charles River Laboratories International Inc

CRL

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-15

The company’s current price momentum score is 7.34, which is higher than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 177.30 and the support level at 147.15, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.44

Change

-0.1

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(5)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-2.164

Sell

RSI(14)

40.783

Neutral

STOCH(KDJ)(9,3,3)

26.293

Sell

ATR(14)

5.936

High Vlolatility

CCI(14)

-157.510

Sell

Williams %R

82.620

Oversold

TRIX(12,20)

-0.039

Sell

StochRSI(14)

15.835

Sell

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

155.104

Sell

MA10

158.740

Sell

MA20

159.798

Sell

MA50

160.552

Sell

MA100

149.624

Buy

MA200

158.125

Sell

Institutional Confidence

Currency: USD Updated：2025-09-15

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 6.02. The latest institutional shareholding proportion is 114.06%, representing a quarter-over-quarter increase of 1.19%. The largest institutional shareholder is The Vanguard, holding a total of 5.80M shares, representing 11.79% of shares outstanding, with 1.73% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

6.09M

-0.65%

Wellington Management Company, LLP

4.29M

+5.12%

BlackRock Institutional Trust Company, N.A.

2.91M

-1.45%

Allspring Global Investments, LLC

1.77M

-1.85%

State Street Global Advisors (US)

1.90M

-12.78%

Nomura Securities Co., Ltd.

601.62K

+95.46%

Ariel Investments, LLC

Star Investors

1.10M

+3.13%

Geode Capital Management, L.L.C.

1.26M

+2.47%

Invesco Capital Management LLC

Star Investors

981.66K

+8.66%

Risk Assessment

Currency: USD Updated：2025-09-15

The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Biotechnology & Medical Research mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 3.21, which is lower than the Biotechnology & Medical Research industry's average of 3.51. The company's beta value is 1.47. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.